Evolving Insights Into EZH 1/2 Inhibition in B- and T-Cell Lymphoma: Expert Perspectives on Latest Advancements

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

2026-09-23- KSR - Hour 2 51 min · 23 Sep 2026 · KSR

Kevin Harlan Is As Good As Anyone In Football | Hour 2 36 min · 23 Sep 2026 · The Dan Le Batard Show

12PM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

2026-09-23- KSR - Hour 1 51 min · 23 Sep 2026 · KSR

A Dreamy Journey with a Dragon 56 min · 23 Sep 2026 · Get Sleepy: stories for sleep

American Idol Murder Trial: Wife’s Family Testifies, “We Loved Caleb So Much, We Didn’t Question Anything” 32 min · 23 Sep 2026 · Amy Robach & T.J. Holmes Present

Report any issue

Source

Recorded28 Aug 2026

Publisherc.answersincme.com ↗

Handlerec:20177586

Show notes

Please visit answersincme.com/NDX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tycel J. Phillips, MD and Steven Horwitz, MD. In this activity, experts in B-cell and T-cell lymphomas discuss EZH inhibitors for non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Discuss the rationale for EZH inhibitors in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL); Describe the clinical profiles of available and emerging EZH inhibitors; and Outline current and potential methods of optimizing EZH inhibitors in clinical practice based on available evidence.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in